Should we consider MMF therapy after rituximab for nephrotic syndrome?

Pediatric Nephrology

Volumn 26, Issue 10, 2011, Pages 1759-1762

  Filler, Guido ^a,b   Huang, Shih Han Susan ^a   Sharma, Ajay P ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Evidence based treatment; MMF; Rituximab; Steroid dependent nephrotic syndrome

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN; LEVAMISOLE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

AGAMMAGLOBULINEMIA; B LYMPHOCYTE; CHILDHOOD DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG COST; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; FOCAL GLOMERULOSCLEROSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME;

EID: 80052298802     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1894-x     Document Type: Review

References (24)

1. Anonymous (no authors listed) (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159-165
2. Hodson EM, Knight JF, Willis NS, Craig JC (2003) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2003(1):CD001533
3. N MacHardy PV Miles SF Massengill WE Smoyer JD Mahan L Greenbaum S Massie L Yao S Nagaraj JJ Lin D Wigfall H Trachtman Y Hu DS Gipson 2009 Management patterns of childhood-onset nephrotic syndrome Pediatr Nephrol 24 2193 2201 19672630 10.1007/s00467-009-1282-y
4. KV Lieberman A Tejani 1996 A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children J Am Soc Nephrol 7 56 63 8808110 1:CAS:528:DyaK28Xhs1Shtb0%3D (Pubitemid 26068448)
5. DC Cattran GB Appel LA Hebert LG Hunsicker MA Pohl WE Hoy DR Maxwell CL Kunis 1999 A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group Kidney Int 56 2220 2226 10594798 1:CAS:528:DC%2BD3cXisVChtA%3D%3D 10.1046/j.1523-1755.1999.00778.x (Pubitemid 30004751)
6. Filler G (2003) Treatment of nephrotic syndrome in children and controlled trials. Nephrol Dial Transplant 18(Suppl 6):vi75-vi78 (Pubitemid 37098599)
7. C Plank V Kalb B Hinkes F Hildebrandt O Gefeller W Rascher 2008 Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome - a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie Pediatr Nephrol 23 1483 1493 18481113 10.1007/s00467-008-0794-1
8. British Association of Pediatric Nephrology (1991) Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 337:1555-1557
9. J Gellermann U Querfeld 2004 Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil Pediatr Nephrol 19 101 104 14753204 10.1007/s00467-003-1300-4 (Pubitemid 38088259)
10. DS Gipson H Trachtman FJ Kaskel MK Radeva J Gassman TH Greene MM Moxey-Mims RJ Hogg SL Watkins RN Fine JP Middleton VM Vehaskari SL Hogan S Vento PA Flynn LM Powell JL McMahan N Siegel AL Friedman 2011 Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life Kidney Int 79 678 685 21178977 1:CAS:528:DC%2BC3MXisFalsrw%3D 10.1038/ki.2010.485
11. K Benz J Dotsch W Rascher D Stachel 2004 Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy Pediatr Nephrol 19 794 797 15071769 10.1007/s00467-004-1434-z (Pubitemid 38931165)
12. K Nozu K Iijima M Fujisawa A Nakagawa N Yoshikawa M Matsuo 2005 Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome Pediatr Nephrol 20 1660 1663 16133051 10.1007/s00467-005-2013-7 (Pubitemid 41554486)
13. H Francois E Daugas A Bensman P Ronco 2007 Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations Am J Kidney Dis 49 158 161 17185157 1:CAS:528:DC%2BD2sXhsFSjsbs%3D 10.1053/j.ajkd.2006.10.015 (Pubitemid 44932200)
14. V Guigonis A Dallocchio V Baudouin M Dehennault C Hachon-Le Camus M Afanetti J Groothoff B Llanas P Niaudet H Nivet N Raynaud S Taque P Ronco F Bouissou 2008 Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases Pediatr Nephrol 23 1269 1279 18465150 10.1007/s00467-008-0814-1
15. A Prytula K Iijima K Kamei D Geary E Gottlich A Majeed M Taylor SD Marks S Tuchman R Camilla M Ognjanovic G Filler G Smith K Tullus 2010 Rituximab in refractory nephrotic syndrome Pediatr Nephrol 25 461 468 20033225 10.1007/s00467-009-1376-6
16. M Suri K Tran AP Sharma G Filler J Grimmer 2008 Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab Int Urol Nephrol 40 807 810 18491215 1:CAS:528:DC%2BD1cXptVChsrw%3D 10.1007/s11255-008-9393-0
17. AP Sharma G Filler 2009 Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab Pediatr Nephrol 24 423 424 18853197 10.1007/s00467-008-1030-8
18. S Ito K Kamei M Ogura M Sato T Fuijimaru T Ishikawa T Udagawa I Kazumoto 2011 Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome Pediat Nephrol 10.1007/s00467-011-1886-x
19. M van Husen MJ Kemper 2011 New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome Pediatr Nephrol 10.1007/s00467-010-1717-5 21229269
20. G Filler N Lepage 2004 To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription Pediatr Nephrol 19 962 965 15257455 (Pubitemid 39242775)
21. B Tonshoff E David-Neto R Ettenger G Filler T van Gelder J Goebel DR Kuypers E Tsai AA Vinks LT Weber LB Zimmerhackl 2011 Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation Transplant Rev 10.1016/j.trre.2011.01.001
22. DS Ardelean T Gonska S Wires E Cutz A Griffiths E Harvey SM Tse SM Benseler 2010 Severe ulcerative colitis after rituximab therapy Pediatrics 126 e243 e246 20566611 10.1542/peds.2009-3395
23. K Kamei S Ito K Iijima 2010 Severe respiratory adverse events associated with rituximab infusion Pediatr Nephrol 25 1193 20024586 10.1007/s00467-009- 1408-2
24. MC Chaumais A Garnier F Chalard M Peuchmaur S Dauger E Jacqz-Agrain G Deschenes 2009 Fatal pulmonary fibrosis after rituximab administration Pediatr Nephrol 24 1753 1755 19396468 10.1007/s00467-009-1195-9